Compare GRC & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | KLRA |
|---|---|---|
| Founded | 1933 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1994 | 2026 |
| Metric | GRC | KLRA |
|---|---|---|
| Price | $71.07 | $13.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 110.4K | ★ 808.7K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $682,389,000.00 | N/A |
| Revenue This Year | $6.62 | N/A |
| Revenue Next Year | $4.66 | N/A |
| P/E Ratio | $52.82 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $42.31 | $13.90 |
| 52 Week High | $92.78 | $23.82 |
| Indicator | GRC | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 33.33 |
| Support Level | $68.94 | N/A |
| Resistance Level | $73.24 | $19.02 |
| Average True Range (ATR) | 2.02 | 1.22 |
| MACD | -0.25 | -0.23 |
| Stochastic Oscillator | 1.92 | 3.42 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.